A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Adavosertib (Primary) ; Irinotecan (Primary)
- Indications Carcinoma; Ependymoma; Germ cell and embryonal neoplasms; Glioma; Medulloblastoma; Neuroblastoma; Osteosarcoma; Primitive neuroectodermal tumours; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Adverse reactions; Pharmacokinetics
- 31 Aug 2018 Biomarkers information updated
- 07 Nov 2017 Planned number of patients changed from 128 to 154.
- 23 Oct 2017 Planned primary completion date changed from 31 Oct 2017 to 30 Apr 2021.